TY - JOUR
T1 - Economic impact of chronic prostatitis
AU - Duloy, Anna M.S.
AU - Calhoun, Elizabeth A.
AU - Clemens, J. Quentin
N1 - Funding Information:
Later in her career, Dr. Kirksey was part of a consortium funded by the US Agency for International Development who investigated nutrition in 3 developing countries: Egypt, Kenya, and Mexico. From 1982 to 1992, Nell was the principal investigator at Purdue University with a focus on understanding the effects of marginal malnutrition in the rural village of Kamala, Egypt. She visited Egypt several times in connection with this project, and she thoroughly enjoyed her collaborations with research scientists there. This work strongly linked domains of nutritional biochemistry, nutrient metabolism, and public health application. One of the seminal contributions of this work was that even small amounts of animal foods in the diet improved development and cognitive function ( 9 ). Millions of infants in developed and developing countries alike have been the benefactors of her work. George McCabe from the Department of Statistics and Ted Wachs from the Department of Psychological Sciences at Purdue were key collaborators on these studies.
Funding Information:
Nell was a tireless and innovative researcher during her long and productive career. Her dynamic and imaginative research program brefidged the gap from basic mechanistic science to an applied understanding of diet and human development on an international scale. She spent her career in the Department of Foods and Nutrition at Purdue, from her PhD in 1961 until her retirement in 1994. She took a sabbatical split between 2 places, the Letterman Army Institute and the University of California–Davis. For most of her career, her research focused on the role of vitamin B-6 in infant development, work that led to a better understanding of the relation between diet and human behavior and cognition ( 1–4 ). Early in her career, this work was largely supported by Purdue's Agricultural Experiment Station, a typical source of support for nutrition researchers in a land grant university until the 1970s. Nutrition departments had few research scientists and Hatch funds could support a modest-sized laboratory. When Paul Abernathy, her Department Head, suggested to Nell that she apply for external grants to the NIH or USDA, Nell asked which one he recommended. He said either one, so Nell wrote grant applications to both agencies and received them both.
PY - 2007/7
Y1 - 2007/7
N2 - There are four types of prostatitis, including type I (acute bacterial prostatitis), type II (chronic bacterial prostatitis), type 111 (chronic prostatitis/chronic pelvic pain syndrome, or CP/CPPS), and type IV (asymptomatic inflammatory prostatitis). These prostatitis conditions account for approximately 2 million office visits each year to primary care physicians and urologists. The annual cost to treat prostatitis is approximately $84 million. Compared with control subjects, men with prostatitis incur significantly greater costs, predominantly due to increased outpatient visits and pharmacy expenses. CP/CPPS is the most common type of prostatitis. The condition is characterized by chronic, idiopathic pelviperineal pain. Due to the lack of effective treatments for CP/CPPS, the per-person costs associated with the condition are substantial and are similar to those reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid arthritis. Costs appear to be higher in men with more severe symptoms. Indirect costs (eg, work and productivity loss) are incurred by many patients with CP/CPPS. Identification of effective treatments for CP/CPPS would be expected to substantially reduce the costs associated with the condition.
AB - There are four types of prostatitis, including type I (acute bacterial prostatitis), type II (chronic bacterial prostatitis), type 111 (chronic prostatitis/chronic pelvic pain syndrome, or CP/CPPS), and type IV (asymptomatic inflammatory prostatitis). These prostatitis conditions account for approximately 2 million office visits each year to primary care physicians and urologists. The annual cost to treat prostatitis is approximately $84 million. Compared with control subjects, men with prostatitis incur significantly greater costs, predominantly due to increased outpatient visits and pharmacy expenses. CP/CPPS is the most common type of prostatitis. The condition is characterized by chronic, idiopathic pelviperineal pain. Due to the lack of effective treatments for CP/CPPS, the per-person costs associated with the condition are substantial and are similar to those reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid arthritis. Costs appear to be higher in men with more severe symptoms. Indirect costs (eg, work and productivity loss) are incurred by many patients with CP/CPPS. Identification of effective treatments for CP/CPPS would be expected to substantially reduce the costs associated with the condition.
UR - http://www.scopus.com/inward/record.url?scp=34547401595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547401595&partnerID=8YFLogxK
U2 - 10.1007/s11934-007-0081-x
DO - 10.1007/s11934-007-0081-x
M3 - Review article
C2 - 18519019
AN - SCOPUS:34547401595
SN - 1527-2737
VL - 8
SP - 336
EP - 339
JO - Current Urology Reports
JF - Current Urology Reports
IS - 4
ER -